CN106491840A - 一种缓解视疲劳的组合物及其制备方法 - Google Patents
一种缓解视疲劳的组合物及其制备方法 Download PDFInfo
- Publication number
- CN106491840A CN106491840A CN201610936762.1A CN201610936762A CN106491840A CN 106491840 A CN106491840 A CN 106491840A CN 201610936762 A CN201610936762 A CN 201610936762A CN 106491840 A CN106491840 A CN 106491840A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- jasmine tea
- extract
- relieving asthenopia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims description 22
- 235000010254 Jasminum officinale Nutrition 0.000 claims abstract description 49
- 240000001238 Gaultheria procumbens Species 0.000 claims abstract description 34
- 235000007297 Gaultheria procumbens Nutrition 0.000 claims abstract description 34
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000007938 effervescent tablet Substances 0.000 claims abstract description 24
- 239000011782 vitamin Substances 0.000 claims abstract description 23
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 22
- 239000011734 sodium Substances 0.000 claims abstract description 22
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 22
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960003080 taurine Drugs 0.000 claims abstract description 15
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 14
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 14
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 14
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 14
- 239000002253 acid Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 9
- 241000207840 Jasminum Species 0.000 claims description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 235000005979 Citrus limon Nutrition 0.000 claims description 35
- 244000131522 Citrus pyriformis Species 0.000 claims description 35
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 24
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 24
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 24
- 239000003826 tablet Substances 0.000 claims description 22
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 21
- 241001328788 Camellia nitidissima Species 0.000 claims description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 19
- 241001113925 Buddleja Species 0.000 claims description 18
- 238000005469 granulation Methods 0.000 claims description 18
- 230000003179 granulation Effects 0.000 claims description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 16
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 16
- 239000008101 lactose Substances 0.000 claims description 16
- 241001122767 Theaceae Species 0.000 claims description 15
- 239000011975 tartaric acid Substances 0.000 claims description 15
- 235000002906 tartaric acid Nutrition 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 108010011485 Aspartame Proteins 0.000 claims description 13
- 239000000605 aspartame Substances 0.000 claims description 13
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 13
- 235000010357 aspartame Nutrition 0.000 claims description 13
- 229960003438 aspartame Drugs 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 235000020985 whole grains Nutrition 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 229940083542 sodium Drugs 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 17
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 10
- 229930003268 Vitamin C Natural products 0.000 abstract description 10
- 235000019154 vitamin C Nutrition 0.000 abstract description 10
- 239000011718 vitamin C Substances 0.000 abstract description 10
- 230000007774 longterm Effects 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 206010034960 Photophobia Diseases 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 230000003796 beauty Effects 0.000 abstract description 3
- 230000036772 blood pressure Effects 0.000 abstract description 3
- 210000003238 esophagus Anatomy 0.000 abstract description 3
- 230000004438 eyesight Effects 0.000 abstract description 3
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 3
- 210000000214 mouth Anatomy 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- 230000009849 deactivation Effects 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 240000005385 Jasminum sambac Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- 239000002245 particle Substances 0.000 description 9
- 239000003513 alkali Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 5
- 238000013112 stability test Methods 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 230000001133 acceleration Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000021028 berry Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 150000003625 trehaloses Chemical class 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 208000001491 myopia Diseases 0.000 description 2
- 230000004379 myopia Effects 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000000515 tooth Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical group OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种缓解视疲劳的组合物,该组合物包括以下重量份的组分:维生素C钠50‑100份、牛磺酸10‑20份、葡萄糖酸锌10‑20份、花茶果提取物10‑20份。本发明针对现有含维生素C泡腾片溶解后酸性大、对口腔、咽喉食道以及胃粘膜刺激较大、不宜长期服用,及存储过程中维生素C容易氧化失效,泡腾片易受潮吸湿等问题,提供一种具有提高免疫力、降血糖、血压、血脂,清热、明目、美白养颜等功效,能明显改善视力模糊、眼干涩、眼胀、眼痛、畏光等症状的组合物。
Description
技术领域
本发明属于药品、保健食品、食品领域,涉及一种组合物制剂及其制备方法,特别是涉及一种缓解视疲劳的组合物及其制备方法。
背景技术
随着现代科技的日新月异以及互联网的普及,电脑的使用越来越普遍,我国网民规模达7.1亿,互联网普及率达到51.7%,随着移动通讯网络环境的不断改善以及智能手机的进一步普及,移动互联网应用向网民生活渗透,手机上网使用率也日益增长,目前我国手机网民规模达6.56亿人。电脑、手机辐射对眼睛的伤害越来越大,造成眼疾的患者越来越多,我国近视人数高达4.5亿,青少年近视患病率已高居世界首位,随着年龄的增长,中老年白内障、青光眼等各类眼疾的患病率也逐年递增。为了改善人们日常生活中由于电脑、手机的使用引起的视力模糊、眼干涩、眼胀、眼痛、畏光等症状,从而减少眼疾病的发生,市场上出现了大量缓解视疲劳产品,其功效成份主要以牛磺酸、叶黄素、维生素等化学成份为主,作用比较单一。
维生素C是临床基本常用药物或营养补充剂,是抗氧化维生素当中的一种,它参与体内羟化反应,为形成骨骼、牙齿、结缔组织及非上皮组织细胞间粘物所必需,可维持牙齿、骨骼、血管的正常功能,增加对疾病的抵抗能力,为人体必需的营养元素之一,广泛应用于多种疾病预防和治疗。维生素C钠是维生素C的钠盐,水溶液pH值接近中性,它的作用与维生素C相同,但由于是钠盐,所以性能更稳定,同时不再有维生素C的强酸性,可以长期与多种药物同时服用,更优于维生素C。
泡腾片是近年来国外开发应用的一种新颖片剂。它与普通片剂的不同之处,就在于它还含有泡腾崩解剂,当泡腾片放入饮水中之后,在泡腾崩解剂的作用下,即刻产生大量气泡,使片剂迅速崩解和融化,有时崩解产生的气泡还会使药片在水中上下翻滚,加速其崩解和融化。片剂崩解时产生的气体部分溶解于饮水中,使饮水喝入口中时有汽水般的美感。泡腾片有如下的优点:便于保存和携带;崩解快速、服用方便、起效迅速;生物利用度高,能提高临床疗效;特别适用于儿童、老年人以及吞服药丸困难的患者;经过调味后的泡腾片,口味更佳,良药不再苦口,使消费者或病人更乐于接受。
发明内容
本发明针对现有缓解视疲劳产品作用比较单一以及含维生素C泡腾片溶解后酸性大、对口腔、咽喉食道以及胃粘膜刺激较大、不宜长期服用,及存储过程中维生素C容易氧化失效、泡腾片易吸湿受潮等问题,提供一种缓解视疲劳同时具有提高免疫力、降血糖、血压、血脂,清热、明目、美白养颜等功效的组合物及其制备方法,解决了市面上产品作用比较单一,临床上应用维生素C存在的质量不稳定、不易长期服用的等问题。本发明缓解视疲劳的组合物,安全、无毒副作用,可长期用于改善视力模糊、眼干涩、眼胀、眼痛、畏光等症状;或作为营养补充剂长期服用。
为解决上述技术问题,本发明是通过以下技术方案实现的:
一种缓解视疲劳的组合物,包括以下重量份的组分:维生素C钠50-100份、牛磺酸10-20份、葡萄糖酸锌10-20份、花茶果提取物10-20份。
以上所述花茶果提取物由以下重量份的原料制成:密蒙花40-60份、金花茶20-40份、鲜柠檬5-10份。
以上所述花茶果提取物的制备方法为:
S1:按以下重量份称取原料:密蒙花40-60份、金花茶20-40份、鲜柠檬5-10份;
S2:取称量好的密蒙花、金花茶,加6-10倍量水,浸泡30分钟,提取2-3次,每次30-40分钟,滤过,得花茶提取液;
S3:取称量好的鲜柠檬,洗净,去皮,榨取原汁,滤过,得柠檬果汁;
S4:将花茶提取液于柠檬果汁混合,80℃以下减压浓缩,得60℃时相对密度为1.18-1.22的流浸膏,将流浸膏进行干燥,控制干燥温度为65-80℃,得花茶果提取物。
所述步骤S2项下提取方法优选为加热回流提取、超声提取。
所述步骤S4项下干燥方法优选为烘箱加热干燥、喷雾干燥。
以上所述的缓解视疲劳的组合物,优选还包括以下重量份的组分:酒石酸50-100份、碳酸氢钠60-150份、阿斯巴甜20-40份。
以上所述的缓解视疲劳的组合物,进一步优选还包括占以上所述组分总重量0.5-1.0%的海藻糖及占以上所述组分总重量0.3-0.5%的乳糖。
以上所述的缓解视疲劳的组合物,最佳优选包括以下重量份的组分:维生素C钠80份、牛磺酸15份、葡萄糖酸锌15份、花茶果提取物15份、酒石酸70份、碳酸氢钠100份、阿斯巴甜30份,还包括占以上所述组分总重量0.8%的海藻糖及占以上所述组分总重量0.4%的乳糖。
以上所述花茶果提取物最佳优选由以下重量份的原料制成:密蒙花50份、金花茶30份、鲜柠檬8份。
以上所述缓解视疲劳的组合物的制备方法,包括如下步骤:
T1:花茶果提取物的制备:按重量份称取以下原料:密蒙花40-60份、金花茶20-40份、鲜柠檬5-10份;取称量好的密蒙花、金花茶,加6-10倍量水,浸泡30分钟,提取2-3次,每次30-40分钟,滤过,得花茶果提取液;取称量好的鲜柠檬,洗净,去皮,榨取原汁,滤过,得柠檬果汁;将花茶提取液于柠檬果汁混合,80℃以下减压浓缩,得60℃时相对密度为1.18-1.22的流浸膏,将流浸膏进行干燥,控制干燥温度为65-80℃,得花茶果提取物;
T2:按重量份称取以下组分:维生素C钠50-100份、牛磺酸10-20份、葡萄糖酸锌10-20份、花茶果提取物10-20份、酒石酸50-100份、碳酸氢钠60-150份、阿斯巴甜20-40份;再称取占所述组分总重量0.5-1.0%的海藻糖及占所述组分总重量0.3-0.5%的乳糖;
T3:取酒石酸、花茶果提取物总重量的1/2、海藻糖总重量的1/2、阿斯巴甜,混匀,喷入50-60%乙醇溶液,混匀,制粒,过筛,干燥,整粒,得酸剂;
T4:取碳酸氢钠、花茶果提取物总重量的1/2、海藻糖总重量的1/2,混匀,喷入50-60%乙醇溶液,混匀,制粒,过筛,干燥,整粒,得碱剂;
T5:取维生素C钠、牛磺酸、葡萄糖酸锌、酸剂、碱剂、乳糖,混匀,压片,即得。
所述步骤T3、T4项下干燥的温度优选为80℃以下,这样得到的颗粒硬度适中,更有利于压片,同时利用崩解;所述步骤T3、T4项下所述的过筛步骤所用的筛网优选为14-30目。
本发明的有益效果是:
1.本发明克服现有含维生素C泡腾片溶解后酸性大、对口腔、咽喉食道以及胃粘膜刺激较大、不宜长期服用,及存储过程中维生素C容易氧化失效、泡腾片易吸湿受潮等问题,使产品稳定性更好,疗效更确切,适用于消费者或患者长期服用,无副作用。
2.本发明方中花茶果提取物的各原料均为“药食同源”品种,其中密蒙花具祛风,凉血,润肝,明目之功效,用于治疗目赤肿痛,多泪羞明,青盲翳障,风弦烂眼,为眼科专用药;金花茶是一种药用价值、保健价值极高的植物,为广西特有,属无毒级,含有400多种营养物质,经研究表明金花茶对于调节人体血脂、血糖、胆固醇,增强机体免疫力有明显的效果,在民间一直被用于提神醒脑、清肝火、解热毒、养元气;鲜柠檬具有美白护肤、清热化痰、抗菌消炎、预防心血管疾病等功效;三药相伍具有提高免疫力、降血糖、血压、血脂,清热、明目、美白养颜等功效,进一步加强其改善视力模糊、眼干涩、眼胀、眼痛、畏光等症状的作用,克服了市面上缓解视疲劳产品的成份、作用单一的问题。
3.本发明缓解视疲劳的组合物,制剂简便,颗粒流动性好,压片不粘冲,所制得的片剂表面光滑,不易吸湿,泡腾产气均匀,崩解时间短,崩解后溶液透明澄清,口感香甜,质量稳定,携带方便,兼具了固体制剂和液体制剂的特点,尤其适用于儿童、老年人和不能吞咽固体制剂的患者,生物利用度高,使用更安全有效,可作为营养补充液长期服用。
具体实施方式
虽然本说明书通过特别指出并清楚要求保护本发明的权利要求书作出结论,但应该相信下列说明将更好地理解本发明。
如本文所用,单词“优选”及变体是指在特定环境下能够提供特定有益效果的本发明的实施方案。然而,其它的实施方案在相同或其它的环境下也可以是优选的。此外,一个或多个优选实施方案的详述并不表示其它实施方案是无用的,并且不旨在从本发明的范畴排除其它的实施方案。
一、制剂条件筛选
1.酸源和碱源的选择
泡腾片中常用的酸源有酒石酸、柠檬酸、富马酸、己二酸、苹果酸等;碱源有碳酸氢钠、碳酸钾、碳酸氢钾、碳酸钙等。用碳酸氢钠作为碱源制成的泡腾片在水中能迅速崩解,且泡腾溶液的pH值适宜维生素C钠的稳定,故本发明碱源选择碳酸氢钠。在固定碱源为碳酸氢钠的基础上,按下表1中的配方对酒石酸、柠檬酸、富马酸、苹果酸、己二酸进行选择试验,以确定泡腾片中最佳的酸源种类。
表1酸源和碱源优选试验
从表1中的试验结果可知:本发明使用酒石酸与维生素C钠、碳酸氢钠、阿斯巴甜混和,好制粒,腾崩解时间短,溶液澄清,口感好,只是压片时有粘冲现象,相比其他酸源最好,故本发明酸源选择酒石酸,碱源选择碳酸氢钠。
2.粘合剂选择
本发明对比了干法压片、湿法制粒再压片,干法压片采用普通压片机效果不好,对设备要求高,故本发明采用湿法制粒再压片。试验中对比了30%淀粉浆、40%蔗糖糖浆、5%羟丙甲纤维素水溶液、55%乙醇做粘合剂,结果见表2。
表2粘合剂考察结果表
从表2中的试验结果可知:本发明使用55%乙醇制粒情况及泡腾效果最好,故本发明粘合剂选择55%乙醇。为进一步优化乙醇浓度,本发明继续优化乙醇浓度,试验结果见表3。
表3乙醇浓度考察结果表
序号 | 粘合剂 | 制粒情况 | 颗粒外观 | 泡腾效果 |
1 | 20%乙醇 | 不成团,制粒困难 | 颗粒松 | 泡腾崩解时间3分钟,溶液澄清 |
2 | 30%乙醇 | 不成团,制粒困难 | 颗粒松紧合适 | 泡腾崩解时间3分钟,溶液澄清 |
3 | 50%乙醇 | 成团,制粒不结块 | 颗粒松紧合适 | 泡腾崩解时间3.5分钟,溶液澄清 |
4 | 60%乙醇 | 成团,制粒不结块 | 颗粒松紧合适 | 泡腾崩解时间3.5分钟,溶液澄清 |
5 | 70%乙醇 | 成团,制粒结块 | 颗粒紧 | 泡腾崩解时间6.0分钟,溶液澄清 |
从表3中的试验结果可知:本发明使用50%-60%乙醇制粒情况及泡腾效果较好,浓度低太松,浓度太高影响泡腾时间,故本发明粘合剂选择50%-60%乙醇。
3.稳定剂的选择
维生素C钠是维生素C的钠盐,性能较维生素C更稳定,但制备成泡腾片剂,在酸剂、碱剂、其他辅料及空气中水分及氧化等的影响,要在保质期内保证产品的质量稳定,还是需要加入稳定剂。试验中对比了0.02%EDTA二钠、1%海藻糖、0.2%亚硫酸钠,将分别用上述稳定剂制成的样品,分别用铝塑复合膜包装好,置稳定性加速试验箱内试验:温度:40±2℃,相对湿度:75±5%,加速试验3个月,试验结果见表4。
表4稳定剂试验结果表
从表4中的试验结果可知:采用EDTA二钠及亚硫酸钠作为稳定剂,含水量变化较大,容易造成酸剂碱剂内部反应,溶液pH降低及加速氧化,导致维生素C钠含量降低。以1%海藻糖为稳定剂,加速试验后,水分变化不大,外观、泡腾反应时间、溶液pH及维生素C钠含量变化小,故本发明使用1%海藻糖作为稳定剂,为此,进一步考察海藻糖的加入量并将所得样品进行加速试验,试验方法同表4,结果详见表5。
表5海藻糖的加入量试验结果表
从表5中的试验结果可知:加入0.2-0.4%海藻糖后泡腾片的水分、外观、泡腾反应时间、溶液pH及维生素C钠含量变化均较大;而含0.5-1.0%海藻糖的泡腾片各项理化指标在3个月的加速时间内变化小,质量稳定;含1.2-1.5%海藻糖的泡腾片在3个月的加速时间内外观、pH值、含量指标变化不大,3个月加速时间内质量仍稳定,但水分、泡腾反应时间变化超出质量标准规定。故本发明控制海藻糖的加入量为0.5-1.0%。
4.润滑剂的选择
本发明在压片前的物料有酸剂、维生素C钠、甜味剂、碱剂,物料颗粒大小、质地不均,压片时出现颗粒流动性差、压片时易粘冲等现象。本发明试验中除润滑剂外其余配方相同,经初步试验确定可用比例后,具体对比了不同加入量的十二烷基硫酸镁、乳糖、甘露醇,并将分别用上述润滑剂制成的样品,分别用铝塑复合膜包装好,置稳定性加速试验箱内试验:温度:40±2℃,相对湿度:75±5%,加速试验3个月,结果见表6。
表6润滑剂试用结果表
从表6中的试验结果可知:加入0.3-0.5%乳糖的流动性好,且压片不粘冲,片面光滑美观,但加速试验发现,加入乳糖量增加,含水量增加,泡腾反应时间也增加很多,不符合泡腾剂崩解时间要求,故本发明选用0.3-0.5%的乳糖作为润滑剂。
二、缓解视疲劳的组合物的制备方法
实施例1
缓解视疲劳的组合物的制备方法,包括如下步骤:
T1:花茶果提取物的制备:按重量份称取以下原料:密蒙花40份、金花茶40份、鲜柠檬5份;取称量好的密蒙花、金花茶,加6倍量水,浸泡30分钟,加热回流提取3次,每次30分钟,滤过,得花茶提取液;取称量好的鲜柠檬,洗净,去皮,榨取原汁,滤过,得柠檬果汁;将花茶提取液与柠檬果汁混合,80℃以下减压浓缩,得60℃时相对密度为1.20的流浸膏,将流浸膏进行喷雾干燥,控制干燥温度为70℃,得花茶果提取物;
T2:按重量份称取以下组分:维生素C钠50份、牛磺酸10份、葡萄糖酸锌10份、花茶果提取物10份、酒石酸50份、碳酸氢钠60份、阿斯巴甜20份;再称取占所述组分总重量0.5%的海藻糖及占所述组分总重量0.3%的乳糖;
T3:取酒石酸、花茶果提取物总重量的1/2、海藻糖总重量的1/2、阿斯巴甜,混匀,喷入50%乙醇溶液,混匀,制粒,过20目筛,80℃下干燥,整粒,得酸剂;
T4:取碳酸氢钠、花茶果提取物总重量的1/2、海藻糖总重量的1/2,混匀,喷入50%乙醇溶液,混匀,制粒,过20目筛,80℃下干燥,整粒,得碱剂;
T5:取维生素C钠、牛磺酸、葡萄糖酸锌、酸剂、碱剂、乳糖,混匀,压片,即得。
实施例2
缓解视疲劳的组合物的制备方法,包括如下步骤:
T1:花茶果提取物的制备:按重量份称取以下原料:密蒙花50份、金花茶30份、鲜柠檬7份;取称量好的密蒙花、金花茶,加8倍量水,浸泡30分钟,加热回流提取2次,每次40分钟,滤过,得花茶提取液;取称量好的鲜柠檬,洗净,去皮,榨取原汁,滤过,得柠檬果汁;将花茶提取液与柠檬果汁混合,80℃以下减压浓缩,得60℃时相对密度为1.18的流浸膏,将流浸膏进行喷雾干燥,控制干燥温度为80℃,得花茶果提取物;
T2:按重量份称取以下组分:维生素C钠80份、牛磺酸15份、葡萄糖酸锌15份、花茶果提取物15份、酒石酸70份、碳酸氢钠100份、阿斯巴甜30份;再称取占所述组分总重量0.8%的海藻糖及占所述组分总重量0.4%的乳糖;
T3:取酒石酸、花茶果提取物总重量的1/2、海藻糖总重量的1/2、阿斯巴甜,混匀,喷入55%乙醇溶液,混匀,制粒,过30目筛,80℃下干燥,整粒,得酸剂;
T4:取碳酸氢钠、花茶果提取物总重量的1/2、海藻糖总重量的1/2,混匀,喷入55%乙醇溶液,混匀,制粒,过30目筛,80℃下干燥,整粒,得碱剂;
T5:取维生素C钠、牛磺酸、葡萄糖酸锌、酸剂、碱剂、乳糖,混匀,压片,即得。
实施例3
缓解视疲劳的组合物的制备方法,包括如下步骤:
T1:花茶果提取物的制备:按重量份称取以下原料:密蒙花60份、金花茶40份、鲜柠檬10份;取称量好的密蒙花、金花茶,加10倍量水,浸泡30分钟,超声提取3次,每次40分钟,滤过,得花茶提取液;取称量好的鲜柠檬,洗净,去皮,榨取原汁,滤过,得柠檬果汁;将花茶提取液与柠檬果汁混合,80℃以下减压浓缩,得60℃时相对密度为1.22的流浸膏,将流浸膏放进烘箱进行加热干燥,控制干燥温度为65℃,得花茶果提取物;
T2:按重量份称取以下组分:维生素C钠100份、牛磺酸20份、葡萄糖酸锌20份、花茶果提取物20份、酒石酸100份、碳酸氢钠150份、阿斯巴甜40份;再称取占所述组分总重量1.0%的海藻糖及占所述组分总重量0.5%的乳糖;
T3:取酒石酸、花茶果提取物总重量的1/2、海藻糖总重量的1/2、阿斯巴甜,混匀,喷入60%乙醇溶液,混匀,制粒,过14目筛,80℃下干燥,整粒,得酸剂;
T4:取碳酸氢钠、花茶果提取物总重量的1/2、海藻糖总重量的1/2,混匀,喷入60%乙醇溶液,混匀,制粒,过14目筛,80℃下干燥,整粒,得碱剂;
T5:取维生素C钠、牛磺酸、葡萄糖酸锌、酸剂、碱剂、乳糖,混匀,压片,即得。
三、稳定性试验
将上述实施例1-3样品分别用铝塑复合膜包装好,置稳定性加速试验箱内试验:温度:40±2℃,相对湿度:75±5%,加速试验3个月,结果实施例1-3样品的外观性状、水分、泡腾反应时间、溶液pH值、主要成分含量等稳定性重点考察指标与0时样品测定结果比较,均无明显变化,说明本发明实施例1-3样品质量较为稳定,可满足贮存、运输、使用的稳定性要求。试验结果见表7。
表7缓解视疲劳的泡腾片稳定性试验结果表
Claims (12)
1.一种缓解视疲劳的组合物,其特征在于,包括以下重量份的组分:维生素C钠50-100份、牛磺酸10-20份、葡萄糖酸锌10-20份、花茶果提取物10-20份;
所述花茶果提取物由以下重量份的原料制成:密蒙花40-60份、金花茶20-40份、鲜柠檬5-10份。
2.如权利要求1所述的缓解视疲劳的组合物,其特征在于,所述花茶果提取物的制备方法为:
S1:按以下重量份称取原料:密蒙花40-60份、金花茶20-40份、鲜柠檬5-10份;
S2:取称量好的密蒙花、金花茶,加6-10倍量水,浸泡30分钟,提取2-3次,每次30-40分钟,滤过,得花茶提取液;
S3:取称量好的鲜柠檬,洗净,去皮,榨取原汁,滤过,得柠檬果汁;
S4:将花茶提取液与柠檬果汁混合,80℃以下减压浓缩,得60℃时相对密度为1.18-1.22的流浸膏,将流浸膏进行干燥,控制干燥温度为65-80℃,得花茶果提取物。
3.如权利要求2所述的缓解视疲劳的组合物,其特征在于,步骤S2项下提取方法为加热回流提取、超声提取。
4.如权利要求2所述的缓解视疲劳的组合物,其特征在于,步骤S4项下干燥方法为烘箱加热干燥、喷雾干燥。
5.如权利要求2-4所述的缓解视疲劳的组合物,其特征在于,加辅料制成保健食品、食品上允许的制剂。
6.如权利要求5所述的缓解视疲劳的组合物,其特征在于,所述制剂为颗粒剂、丸剂、片剂、胶囊、口服液、糖浆剂、饮料或茶饮。
7.如权利要求6所述的缓解视疲劳的组合物,其特征在于,所述片剂为泡腾片。
8.一种如权利要求7所述的缓解视疲劳的组合物制成泡腾片,其特征在于,还包括以下重量份的组分:酒石酸50-100份、碳酸氢钠60-150份、阿斯巴甜20-40份。
9.如权利要求8所述的缓解视疲劳的组合物制成泡腾片,其特征在于,还包括占以上所述组分总重量0.5-1.0%的海藻糖及占以上所述组分总重量0.3-0.5%的乳糖。
10.一种如权利要求9所述的缓解视疲劳的组合物制成泡腾片的方法,其特征在于,包括以下步骤:
T1:花茶果提取物的制备:按重量份称取以下原料:密蒙花40-60份、金花茶20-40份、鲜柠檬5-10份;取称量好的密蒙花、金花茶,加6-10倍量水,浸泡30分钟,提取2-3次,每次30-40分钟,滤过,得花茶提取液;取称量好的鲜柠檬,洗净,去皮,榨取原汁,滤过,得柠檬果汁;将花茶提取液与柠檬果汁混合,80℃以下减压浓缩,得60℃时相对密度为1.18-1.22的流浸膏,将流浸膏进行干燥,控制干燥温度为65-80℃,得花茶果提取物;T2:按重量份称取以下组分:维生素C钠50-100份、牛磺酸10-20份、葡萄糖酸锌10-20份、花茶果提取物10-20份、酒石酸50-100份、碳酸氢钠60-150份、阿斯巴甜20-40份;再称取占所述组分总重量0.5-1.0%的海藻糖及占所述组分总重量0.3-0.5%的乳糖;
T3:取酒石酸、花茶果提取物总重量的1/2、海藻糖总重量的1/2、阿斯巴甜,混匀,喷入50-60%乙醇溶液,混匀,制粒,过筛,干燥,整粒,得酸剂;
T4:取碳酸氢钠、花茶果提取物总重量的1/2、海藻糖总重量的1/2,混匀,喷入50-60%乙醇溶液,混匀,制粒,过筛,干燥,整粒,得碱剂;
T5:取维生素C钠、牛磺酸、葡萄糖酸锌、酸剂、碱剂、乳糖,混匀,压片,即得。
11.如权利要求8所述的缓解视疲劳的组合物制成泡腾片的方法,其特征在于,步骤T3、T4项下干燥的温度为80℃以下。
12.如权利要求8所述的缓解视疲劳的组合物制成泡腾片的方法,其特征在于,步骤T3、T4项下所述的过筛步骤所用的筛网为14-30目。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610936762.1A CN106491840A (zh) | 2016-10-24 | 2016-10-24 | 一种缓解视疲劳的组合物及其制备方法 |
PCT/CN2017/114288 WO2018077311A1 (zh) | 2016-10-24 | 2017-12-01 | 一种缓解视疲劳的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610936762.1A CN106491840A (zh) | 2016-10-24 | 2016-10-24 | 一种缓解视疲劳的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106491840A true CN106491840A (zh) | 2017-03-15 |
Family
ID=58319948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610936762.1A Pending CN106491840A (zh) | 2016-10-24 | 2016-10-24 | 一种缓解视疲劳的组合物及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN106491840A (zh) |
WO (1) | WO2018077311A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107455700A (zh) * | 2017-08-11 | 2017-12-12 | 防城港圣保堂制药有限公司 | 一种含桑葚的离子维c组合物及其制备方法 |
WO2018077312A1 (zh) * | 2016-10-24 | 2018-05-03 | 广西圣保堂健康产业股份有限公司 | 一种增强免疫力的泡腾片及其制备方法 |
WO2018077311A1 (zh) * | 2016-10-24 | 2018-05-03 | 广西圣保堂健康产业股份有限公司 | 一种缓解视疲劳的组合物及其制备方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110711246B (zh) * | 2019-11-20 | 2023-04-14 | 大连迪麦医疗科技有限公司 | 一种改善眼部疲劳及疾病的抗氧化组合物富氢水喷雾及其制备方法 |
CN113598249A (zh) * | 2021-08-10 | 2021-11-05 | 山西中医药大学 | 一种黄芪明目袋泡茶的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1334097A (zh) * | 2000-07-17 | 2002-02-06 | 上海交大昂立股份有限公司 | 一种改善视觉功能的保健品 |
CN102960805A (zh) * | 2012-12-03 | 2013-03-13 | 潘明权 | 一种缓解视疲劳的保健饮料的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106491840A (zh) * | 2016-10-24 | 2017-03-15 | 广西圣保堂健康产业股份有限公司 | 一种缓解视疲劳的组合物及其制备方法 |
CN107050192A (zh) * | 2016-10-28 | 2017-08-18 | 广西圣保堂健康产业股份有限公司 | 一种保护视力的组合物及其制备方法 |
-
2016
- 2016-10-24 CN CN201610936762.1A patent/CN106491840A/zh active Pending
-
2017
- 2017-12-01 WO PCT/CN2017/114288 patent/WO2018077311A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1334097A (zh) * | 2000-07-17 | 2002-02-06 | 上海交大昂立股份有限公司 | 一种改善视觉功能的保健品 |
CN102960805A (zh) * | 2012-12-03 | 2013-03-13 | 潘明权 | 一种缓解视疲劳的保健饮料的制备方法 |
Non-Patent Citations (3)
Title |
---|
娄桂芹 等: "维生素C泡腾片的处方和制备工艺", 《中国煤炭工业医学杂志》 * |
廖小明 主编: "《药物制剂流程与质量监督检验鉴别检查分析测定实用手册》", 31 August 2003, 北京电子出版物出版中心 * |
王岁楼 主编: "《食品生物技术》", 28 February 1999, 海洋出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018077312A1 (zh) * | 2016-10-24 | 2018-05-03 | 广西圣保堂健康产业股份有限公司 | 一种增强免疫力的泡腾片及其制备方法 |
WO2018077311A1 (zh) * | 2016-10-24 | 2018-05-03 | 广西圣保堂健康产业股份有限公司 | 一种缓解视疲劳的组合物及其制备方法 |
CN107455700A (zh) * | 2017-08-11 | 2017-12-12 | 防城港圣保堂制药有限公司 | 一种含桑葚的离子维c组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2018077311A1 (zh) | 2018-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106552105A (zh) | 一种增强免疫力的泡腾片及其制备方法 | |
CN106491840A (zh) | 一种缓解视疲劳的组合物及其制备方法 | |
CN106562438A (zh) | 一种增强免疫力的组合物及其制备方法 | |
CN106387585A (zh) | 牛磺酸电解质运动固体饮料及其生产工艺 | |
CN106173671A (zh) | 一种百合银耳颗粒饮料及其制备方法 | |
CN108497420A (zh) | 蜂王浆保健品 | |
CN102823874A (zh) | 一种石榴泡腾片及其制备方法 | |
CN102687781B (zh) | 苦荞茶泡腾片及其制备方法 | |
CN113575805A (zh) | 一种缓解体力疲劳的山楂黄精枸杞汁饮料及制备方法 | |
CN101828738B (zh) | 防治糖尿病的保健饮料 | |
CN107050192A (zh) | 一种保护视力的组合物及其制备方法 | |
CN107223979A (zh) | 一种山药黄精泡腾片及其制备方法 | |
CN104643243A (zh) | 抗雾霾浆果酵素发酵饮料及其制备方法 | |
CN106819196A (zh) | 一种归脾养心绿茶饮料及其制备方法 | |
CN107375322B (zh) | 儿童及青少年型多种维生素矿物质泡腾片及其制备方法 | |
CN105475800A (zh) | 一种芒果泡腾片及其制备方法 | |
CN106107277A (zh) | 一种油桃饮料及其制备方法 | |
CN102161959A (zh) | 野生沙梨酒及其制作工艺 | |
CN107259024A (zh) | 一种药食两用灵芝人参茶及其制备方法 | |
CN104770528B (zh) | 百合润神茶 | |
CN107048143A (zh) | 一种柠檬苏打水及其生产方法 | |
CN106967578A (zh) | 一种核桃粕糯米营养醋粉的制备方法 | |
CN105918529A (zh) | 一种铁皮石斛红茶及其制备方法 | |
CN106689535A (zh) | 一种三根清肺茶饮料及其制备方法 | |
CN106418274A (zh) | 一种醋制鸡蛋香菇营养保健咀嚼片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170315 |